Animal models for dystonia

Movement Disorders

Volumn 28, Issue 7, 2013, Pages 982-989

  Wilson, Bethany K ^a   Hess, Ellen J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal ganglia; Cerebellum; Mouse model; Primate model

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID;

ANATOMY; BASAL GANGLION; CEREBELLUM; CLINICAL FEATURE; DOPAMINERGIC TRANSMISSION; DYSTONIA; EXPERIMENTAL MODEL; GABAERGIC TRANSMISSION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIMATE; PRIORITY JOURNAL; PURKINJE CELL; REVIEW; RODENT; SIGNAL TRANSDUCTION; SYMPTOM;

EID: 84880811744     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25526     Document Type: Review

References (121)

1. Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985;108:463-483.
2. Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry 1985;48:650-657.
3. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859-876.
4. Obeso JA, Gimenez-Roldan S. Clinicopathological correlation in symptomatic dystonia. Adv Neurol 1988;50:113-122.
5. Neychev VK, Gross RE, Lehericy S, Hess EJ, Jinnah HA. The functional neuroanatomy of dystonia. Neurobiol Dis 2011;42:185-201.
6. Zoons E, Booij J, Nederveen AJ, Dijk JM, Tijssen MA. Structural, functional and molecular imaging of the brain in primary focal dystonia-a review. Neuroimage 2011;56:1011-1020.
7. Carbon M, Argyelan M, Habeck C, et al. Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. Brain 2010;133:690-700.
8. Niethammer M, Carbon M, Argyelan M, Eidelberg D. Hereditary dystonia as a neurodevelopmental circuit disorder: evidence from neuroimaging. Neurobiol Dis 2011;42:202-209.
9. Galardi G, Perani D, Grassi F, et al. Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. Acta Neurol Scand 1996;94:172-176.
10. Magyar-Lehmann S, Antonini A, Roelcke U, et al. Cerebral glucose metabolism in patients with spasmodic torticollis. Mov Disord 1997;12:704-708.
11. Trost M, Carbon M, Edwards C, et al. Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol 2002;52:853-856.
12. Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998;44:303-312.
13. Carbon M, Su S, Dhawan V, Raymond D, Bressman S, Eidelberg D. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. Neurology 2004;62:1384-1390.
14. Ceballos-Baumann AO, Passingham RE, Marsden CD, Brooks DJ. Motor reorganization in acquired hemidystonia. Ann Neurol 1995;37:746-757.
15. Toda H, Hamani C, Lozano A. Deep brain stimulation in the treatment of dyskinesia and dystonia. Neurosurg Focus 2004;17:E2.
16. Krauss JK, Yianni J, Loher TJ, Aziz TZ. Deep brain stimulation for dystonia. J Clin Neurophysiol 2004;21:18-30.
17. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352:459-467.
18. Kostic VS, Stojanovic-Svetel M, Kacar A. Symptomatic dystonias associated with structural brain lesions: report of 16 cases. Can J Neurol Sci 1996;23:53-56.
19. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
20. Ming L. Moldy sugarcane poisoning-a case report with a brief review. J Toxicol Clin Toxicol 1995;33:363-367.
21. He F, Zhang S, Qian F, Zhang C. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology 1995;45:2178-2183.
22. Fu Y, He F, Zhang S, Huang J, Zhang J, Jiao X. 3-Nitropropionic acid produces indirect excitotoxic damage to rat striatum. Neurotoxicol Teratol 1995;17:333-339.
23. Fernagut PO, Diguet E, Stefanova N, et al. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 2002;114:1005-1017.
24. Palfi S, Leventhal L, Goetz CG, et al. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 2000;15:524-530.
25. Palfi S, Ferrante RJ, Brouillet E, et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 1996;16:3019-3025.
26. Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Bioulac B, Tison F. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. Neurosci Lett 2002;335:34-38.
27. Fu Y, He F, Zhang S, Jiao X. Consistent striatal damage in rats induced by 3-nitropropionic acid and cultures of arthrinium fungus. Neurotoxicol Teratol 1995;17:413-418.
28. Loscher W, Fisher JE Jr, Schmidt D, Fredow G, Honack D, Iturrian WB. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov Disord 1989;4:219-232.
29. Fredow G, Loscher W. Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia. Eur J Pharmacol 1991;192:207-219.
30. Hamann M, Richter A. Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. Eur J Pharmacol 2002;443:59-70.
31. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995;38:571-579.
32. Burbaud P, Bonnet B, Guehl D, Lagueny A, Bioulac B. Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. Brain Res 1998;780:102-107.
33. Guehl D, Burbaud P, Boraud T, Bioulac B. Bicuculline injections into the rostral and caudal motor thalamus of the monkey induce different types of dystonia. Eur J Neurosci 2000;12:1033-1037.
34. Macia F, Escola L, Guehl D, Michelet T, Bioulac B, Burbaud P. Neuronal activity in the monkey motor thalamus during bicuculline-induced dystonia. Eur J Neurosci 2002;15:1353-1362.
35. Mink JW, Thach WT. Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement. J Neurophysiol 1991;65:330-351.
36. Wenger KK, Musch KL, Mink JW. Impaired reaching and grasping after focal inactivation of globus pallidus pars interna in the monkey. J Neurophysiol 1999;82:2049-2060.
37. Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012;71:520-530.
38. Hanihara T, Inoue K, Kawanishi C, et al. 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord 1997;12:408-411.
39. Thony B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat 2006;27:870-878.
40. Abeling NG, Duran M, Bakker HD, et al. Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab 2006;89:116-120.
41. Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 2005;128:2291-2296.
42. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994;8:236-242.
43. Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995;4:1209-1212.
44. Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;5:1023-1028.
45. van den Heuvel LP, Luiten B, Smeitink JA, et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population. Hum Genet 1998;102:644-646.
46. Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 2011;10:54-62.
47. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992;42:1980-1988.
48. Brun L, Ngu LH, Keng WT, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 2010;75:64-71.
49. Lloyd KG, Hornykiewicz O, Davidson L, et al. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 1981;305:1106-1111.
50. Saito Y, Ito M, Hanaoka S, Ohama E, Akaboshi S, Takashima S. Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. Neuropediatrics 1999;30:66-71.
51. Bruno MK, Ravina B, Garraux G, et al. Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease. Mov Disord 2004;19:228-230.
52. McKeon A, Matsumoto JY, Bower JH, Ahlskog JE. The spectrum of disorders presenting as adult-onset focal lower extremity dystonia. Parkinsonism Relat Disord 2008;14:613-619.
53. Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia. Adv Neurol 2004;94:53-60.
54. Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology 2002;59:445-448.
55. Horie C, Suzuki Y, Kiyosawa M, et al. Decreased dopamine D receptor binding in essential blepharospasm. Acta Neurol Scand 2009;119:49-54.
56. Hierholzer J, Cordes M, Schelosky L, et al. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. J Nucl Med 1994;35:1921-1927.
57. Naumann M, Pirker W, Reiners K, Lange KW, Becker G, Brucke T. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 1998;13:319-323.
58. Asanuma K, Ma Y, Okulski J, et al. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 2005;64:347-349.
59. Perlmutter JS, Tempel LW, Black KJ, Parkinson D, Todd RD. MPTP induces dystonia and parkinsonism. Clues to the pathophysiology of dystonia. Neurology 1997;49:1432-1438.
60. Tabbal SD, Mink JW, Antenor JA, Carl JL, Moerlein SM, Perlmutter JS. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006;141:1281-1287.
61. Clarke CE, Boyce S, Robertson RG, Sambrook MA, Crossman AR. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). J Neurol Sci 1989;90:307-314.
62. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
63. Neychev VK, Fan X, Mitev VI, Hess EJ, Jinnah HA. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain 2008;131:2499-2509.
64. Lee HY, Nakayama J, Xu Y, et al. Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. J Clin Invest 2012;122:507-518.
65. Song CH, Fan X, Exeter CJ, Hess EJ, Jinnah HA. Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia. Neurobiol Dis 2012;48:68-78.
66. Barrett RE, Yahr MD, Duvoisin RC. Torsion dystonia and spasmodic torticollis-results of treatment with L-dopa. Neurology 1970;20:107-113.
67. Mandell S. The treatment of dystonia with L-dopa and haloperidol. Neurology 1970;20:103-106.
68. Lang AE. Dopamine agonists and antagonists in the treatment of idiopathic dystonia. Adv Neurol 1988;50:561-570.
69. Thiel A, Dressler D, Kistel C, Ruther E. Clozapine treatment of spasmodic torticollis. Neurology 1994;44:957-958.
70. Krauss JK, Seeger W, Jankovic J. Cervical dystonia associated with tumors of the posterior fossa. Mov Disord 1997;12:443-447.
71. Kumandas S, Per H, Gumus H, et al. Torticollis secondary to posterior fossa and cervical spinal cord tumors: report of five cases and literature review. Neurosurg Rev 2006;29:333-338; discussion 338.
72. Rumbach L, Barth P, Costaz A, Mas J. Hemidystonia consequent upon ipsilateral vertebral artery occlusion and cerebellar infarction. Mov Disord 1995;10:522-525.
73. LeDoux MS, Brady KA. Secondary cervical dystonia associated with structural lesions of the central nervous system. Mov Disord 2003;18:60-69.
74. Prudente CN, Pardo CA, Xiao J, et al. Neuropathology of cervical dystonia. Exp Neurol 2012;241C:95-104.
75. Fraioli B, Guidetti. Effects of stereotactic lesions of the dentate nucleus of the cerebellum in man. APPL Neurophysiol 1975;38:81-90.
76. Zervas NT, Horner FG, Gordy PD. Cerebellar dentatectomy in primates and humans. Trans Am Neurol Assoc 1967;92:27-30.
77. Hitchcock E. Dentate lesions for involuntary movement. Proc R Soc Med 1973;66:877-879.
78. Davis R. Cerebellar stimulation for cerebral palsy spasticity, function, and seizures. Arch Med Res 2000;31:290-299.
79. Turgut M, Akalan N, Bertan V, Erbengi A, Eryilmaz M. Acquired torticollis as the only presenting symptom in children with posterior fossa tumors. Childs Nerv Syst 1995;11:86-88.
80. Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci 2009;29:9740-9747.
81. Hutchinson M, Nakamura T, Moeller JR, et al. The metabolic topography of essential blepharospasm. Neurology 2000;55:673-677.
82. Odergren T, Stone-Elander S, Ingvar M. Cerebral and cerebellar activation in correlation to the action-induced dystonia in writer's cramp. Mov Disord 1998;13:497-508.
83. Preibisch C, Berg D, Hofmann E, Solymosi L, Naumann M. Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study. J Neurol 2001;248:10-17.
84. Lehericy S, Gerardin E, Poline JB, et al. Motor execution and imagination networks in post-stroke dystonia. Neuroreport 2004;15:1887-1890.
85. Thobois S, Ballanger B, Xie-Brustolin J, et al. Globus pallidus stimulation reduces frontal hyperactivity in tardive dystonia. J Cereb Blood Flow Metab 2008;28:1127-1138.
86. Campbell DB, Hess EJ. Cerebellar circuitry is activated during convulsive episodes in the tottering (tg/tg) mutant mouse. Neuroscience 1998;85:773-783.
87. Ulug AM, Vo A, Argyelan M, et al. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proc Natl Acad Sci U S A 2011;108:6638-6643.
88. Zhao Y, Sharma N, LeDoux MS. The DYT1 carrier state increases energy demand in the olivocerebellar network. Neuroscience 2011;177:183-194.
89. Brown LL, Lorden JF. Regional cerebral glucose utilization reveals widespread abnormalities in the motor system of the rat mutant dystonic. J Neurosci 1989;9:4033-4041.
90. LeDoux MS, Lorden JF. Abnormal spontaneous and harmaline-stimulated Purkinje cell activity in the awake genetically dystonic rat. Exp Brain Res 2002;145:457-467.
91. Lorden JF, Lutes J, Michela VL, Ervin J. Abnormal cerebellar output in rats with an inherited movement disorder. Exp Neurol 1992;118:95-104.
92. LeDoux MS, Hurst DC, Lorden JF. Single-unit activity of cerebellar nuclear cells in the awake genetically dystonic rat. Neuroscience 1998;86:533-545.
93. Chen G, Popa LS, Wang X, et al. Low-frequency oscillations in the cerebellar cortex of the tottering mouse. J Neurophysiol 2009;101:234-245.
94. Walter JT, Alvina K, Womack MD, Chevez C, Khodakhah K. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat Neurosci 2006;9:389-397.
95. Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid-onset dystonia-Parkinsonism. Nat Neurosci 2011;14:357-365.
96. LeDoux MS, Lorden JF, Ervin J. Cerebellectomy eliminates the motor syndrome of the genetically dystonic rat. Exp Neurol 1993;120:302-310.
97. Campbell DB, North JB, Hess EJ. Tottering mouse motor dysfunction is abolished on the Purkinje cell degeneration (pcd) mutant background. Exp Neurol 1999;160:268-278.
98. Raike RS, Pizoli CE, Weisz C, van den Maagdenberg AM, Jinnah HA, Hess EJ. Limited regional cerebellar dysfunction induces focal dystonia in mice. Neurobiol Dis 2012;49C:200-210.
99. Pizoli CE, Jinnah HA, Billingsley ML, Hess EJ. Abnormal cerebellar signaling induces dystonia in mice. J Neurosci 2002;22:7825-7833.
100. Alvarez-Fischer D, Grundmann M, Lu L, et al. Prolonged generalized dystonia after chronic cerebellar application of kainic acid. Brain Res 2012;1464:82-88.
101. Fan X, Hughes KE, Jinnah HA, Hess EJ. Selective and sustained AMPA receptor activation in cerebellum induces dystonia in mice. J Pharmacol Exp Ther 2012;340:733-741.
102. Hoshi E, Tremblay L, Feger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat Neurosci 2005;8:1491-1493.
103. Ichinohe N, Mori F, Shoumura K. A di-synaptic projection from the lateral cerebellar nucleus to the laterodorsal part of the striatum via the central lateral nucleus of the thalamus in the rat. Brain Res 2000;880:191-197.
104. Li CL, Parker LO. Effect of dentate stimulation on neuronal activity in the globus pallidus. Exp Neurol 1969;24:298-309.
105. Ratcheson RA, Li CL. Effect of dentate stimulation on neuronal activity in the caudate nucleus. Exp Neurol 1969;25:268-281.
106. Nieoullon A, Cheramy A, Glowinski J. Release of dopamine in both caudate nuclei and both substantia nigrae in response to unilateral stimulation of cerebellar nuclei in the cat. Brain Res 1978;148:143-152.
107. Bostan AC, Dum RP, Strick PL. The basal ganglia communicate with the cerebellum. Proc Natl Acad Sci U S A 2010;107:8452-8456.
108. Jinnah HA, Hess EJ. A new twist on the anatomy of dystonia: the basal ganglia and the cerebellum? Neurology 2006;67:1740-1741.
109. Schicatano EJ, Basso MA, Evinger C. Animal model explains the origins of the cranial dystonia benign essential blepharospasm. J Neurophysiol 1997;77:2842-2846.
110. Carpenter MB. A study of the red nucleus in the rhesus monkey; anatomic degenerations and physiologic effects resulting from localized lesions of the red nucleus. J Comp Neurol 1956;105:195-249.
111. Foltz EL, Knopp LM, Ward AA Jr. Experimental spasmodic torticollis. J Neurosurg 1959;16:55-67.
112. Battista AF, Goldstein M, Miyamoto T, Matsumoto Y. Effect of centrally acting drugs on experimental torticollis in monkeys. Adv Neurol 1976;14:329-338.
113. van't Groenewout JL, Stone MR, Vo VN, Truong DD, Matsumoto RR. Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine. Exp Neurol 1995;134:253-260.
114. Messer A, Strominger NL. An allele of the mouse mutant dystonia musculorum exhibits lesions in red nucleus and striatum. Neuroscience 1980;5:543-549.
115. Matsumoto RR, Walker JM. Iontophoretic effects of sigma ligands on rubral neurons in the rat. Brain Res Bull 1992;29:419-425.
116. Asanuma K, Ma Y, Huang C, et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol 2005;57:596-600.
117. Duchen LW. Dystonia musculorum-an inherited disease of the nervous system in the mouse. Adv Neurol 1976;14:353-365.
118. Xiao J, Ledoux MS. Caytaxin deficiency causes generalized dystonia in rats. Brain Res Mol Brain Res 2005;141:181-192.
119. Raike RS, Weisz C, Hoebeek FE, et al. Stress, caffeine and ethanol trigger transient neurological dysfunction through shared mechanisms in a mouse calcium channelopathy. Neurobiol Dis 2013;50:151-159.
120. Ouary S, Bizat N, Altairac S, et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 2000;97:521-530.
121. Matsumoto RR, Hemstreet MK, Lai NL, et al. Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 1990;36:151-155.